HK1071304A1 - Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b - Google Patents
Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5bInfo
- Publication number
- HK1071304A1 HK1071304A1 HK05104181.6A HK05104181A HK1071304A1 HK 1071304 A1 HK1071304 A1 HK 1071304A1 HK 05104181 A HK05104181 A HK 05104181A HK 1071304 A1 HK1071304 A1 HK 1071304A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- formation
- preventing
- complement pathway
- pathway inhibitors
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31313701P | 2001-08-17 | 2001-08-17 | |
PCT/US2002/026074 WO2003015819A1 (en) | 2001-08-17 | 2002-08-17 | Complement pathway inhibitors binding to c5 and c5a without preventing formation of c5b |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1071304A1 true HK1071304A1 (en) | 2005-07-15 |
Family
ID=23214536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05104181.6A HK1071304A1 (en) | 2001-08-17 | 2005-05-19 | Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b |
Country Status (14)
Country | Link |
---|---|
US (6) | US7432356B2 (de) |
EP (1) | EP1425042B2 (de) |
JP (2) | JP4958387B2 (de) |
CN (2) | CN100391537C (de) |
AT (1) | ATE360441T1 (de) |
AU (1) | AU2002331601B2 (de) |
BR (1) | BRPI0211953B8 (de) |
CA (1) | CA2457461C (de) |
DE (1) | DE60219801T3 (de) |
ES (1) | ES2283594T5 (de) |
HK (1) | HK1071304A1 (de) |
MX (2) | MX342385B (de) |
PT (1) | PT1425042E (de) |
WO (1) | WO2003015819A1 (de) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7432356B2 (en) | 2001-08-17 | 2008-10-07 | Genentech, Inc. | Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b |
DE60326264D1 (de) | 2002-12-02 | 2009-04-02 | Resistentia Pharmaceuticals Ab | Verfahren und materialien zur behandlung von entzündungen unter verwendung eines polypeptides das einen eigenen-c5 aminosaüresegment und einen nicht-eigenen aminosaüresegment enthält |
US8329169B2 (en) * | 2003-05-15 | 2012-12-11 | Genentech, Inc. | Methods and compositions for the prevention and treatment of sepsis |
ES2528362T3 (es) | 2004-05-14 | 2015-02-09 | Alexion Pharmaceuticals, Inc. | Prolongación de la supervivencia de un aloinjerto por inhibición de la actividad del complemento |
EP1855111A4 (de) | 2005-03-02 | 2008-10-01 | Astellas Pharma Inc | Neuer pd-marker für einen histon-deacetylase-inhibitor |
RU2007147938A (ru) * | 2005-06-14 | 2009-07-20 | Цитос Биотехнологи Аг (Ch) | Конъюгаты антигенов и их применение |
US20070292421A1 (en) * | 2005-07-28 | 2007-12-20 | Feinberg Bruce B | Method for treating preeclampsia |
KR20150055628A (ko) * | 2005-11-04 | 2015-05-21 | 제넨테크, 인크. | 안질환 치료를 위한 보체 경로 억제제의 용도 |
BRPI0708424A2 (pt) * | 2006-03-02 | 2011-05-31 | Alexion Pharma Inc | prolongamento da sobreviência de uma aloenxerto por inibição da atividade do complemento |
SI2359834T1 (sl) | 2006-03-15 | 2017-02-28 | Alexion Pharmaceuticals, Inc. | Zdravljenje pacientov,ki imajo paroksizmalno nočno hemoglobinurijo, z zaviralcem komplementa |
EP4342995A3 (de) | 2006-03-31 | 2024-05-15 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur kontrolle der blut-pharmazeutizität von antikörpern |
JP5162587B2 (ja) * | 2006-08-22 | 2013-03-13 | ジーツー インフラメイション プロプライエタリー リミテッド | 改良された特性を持つ坑−C5aR抗体 |
PL2061810T3 (pl) | 2006-09-05 | 2015-05-29 | Alexion Pharma Inc | Sposoby i kompozycje do leczenia neuropatii zależnych od przeciwciał |
CL2007003161A1 (es) * | 2006-11-02 | 2008-05-30 | Genentech Inc | Anticuerpos anti-factor d; acidos nucleicos que los codifican; vector y linea celular que los comprenden; metodo de produccion; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar trastornos mediados por el complemento como |
DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
EP3056513A1 (de) | 2008-04-11 | 2016-08-17 | Chugai Seiyaku Kabushiki Kaisha | Antigenbindende moleküle zur wiederholten bindung an zwei oder mehr antigenmoleküle |
CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
MA32975B1 (fr) | 2008-12-22 | 2012-01-02 | Chemocentryx Inc | Antagonistes de c5ar |
EP2327725A1 (de) | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a-bindende Teile mit hoher Blockieraktivität |
BR112012027900A2 (pt) | 2010-04-30 | 2020-05-12 | Alexion Pharmaceuticals, Inc. | Anticorpos anti-c5a e métodos para usar os anticorpos |
SI2585064T1 (sl) | 2010-06-24 | 2017-08-31 | Chemocentryx, Inc. | Antagonisti C5AR |
RU2658504C9 (ru) | 2010-11-30 | 2018-08-21 | Чугаи Сейяку Кабусики Кайся | Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул |
EP2468295A1 (de) | 2010-12-21 | 2012-06-27 | Affiris AG | Impfstoffe basierend auf Komplementprotein C5a Peptide |
DK2718322T3 (en) | 2011-06-06 | 2018-12-03 | Novo Nordisk As | THERAPEUTIC ANTIBODIES |
AU2013222836B2 (en) * | 2012-02-20 | 2017-07-20 | Swedish Orphan Biovitrum Ab (Publ) | Polypeptides binding to human complement C5 |
US9133269B2 (en) | 2012-08-24 | 2015-09-15 | Anaptysbio, Inc. | Humanized antibodies directed against complement protein C5 |
DK2994488T3 (da) * | 2013-05-08 | 2022-10-03 | Novo Nordisk As | Anvendelse af c5ar-antagonister |
US20140335546A1 (en) * | 2013-05-10 | 2014-11-13 | G J Carroll Pty Ltd | Devices and Methods for Determining the Risk of Developing a Serious Infection |
KR20180021234A (ko) | 2013-08-12 | 2018-02-28 | 제넨테크, 인크. | 보체-연관 상태의 치료를 위한 조성물 및 방법 |
PL3039033T3 (pl) | 2013-08-28 | 2020-01-31 | Affibody Ab | Polipeptydy wiążące o zmutowanym rusztowaniu |
ES2842105T3 (es) * | 2013-08-28 | 2021-07-12 | Ipc Res Llc | Polipéptidos estables que se unen a C5 de complemento humano |
NZ631007A (en) * | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
CN106132982A (zh) * | 2014-03-20 | 2016-11-16 | 因弗拉克斯有限责任公司 | 用于治疗病毒性肺炎的C5a抑制剂 |
MA39934A (fr) | 2014-05-01 | 2017-03-08 | Hoffmann La Roche | Variants d'anticorps anti-facteur d et leurs utilisations |
ES2802428T3 (es) | 2014-09-29 | 2021-01-19 | Chemocentryx Inc | Procesos e intermedios en la preparación de antagonistas de C5aR |
TW201809008A (zh) | 2014-12-19 | 2018-03-16 | 日商中外製藥股份有限公司 | 抗c5抗體及使用方法 |
CN107428823B (zh) | 2015-01-22 | 2021-10-26 | 中外制药株式会社 | 两种以上抗-c5抗体的组合与使用方法 |
TW201718014A (zh) | 2015-10-12 | 2017-06-01 | 諾華公司 | C5抑制劑於移植相關微血管病之用途 |
CN108472382A (zh) | 2015-10-30 | 2018-08-31 | 豪夫迈·罗氏有限公司 | 抗-因子d抗体变体缀合物及其用途 |
TW201730211A (zh) | 2015-10-30 | 2017-09-01 | 建南德克公司 | 抗因子d抗體及結合物 |
CA3005592C (en) | 2015-12-18 | 2024-01-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
BR112018014222A2 (pt) | 2016-01-14 | 2018-12-11 | Chemocentryx, Inc. | método de tratamento da glomerulopatia c3 |
KR102534895B1 (ko) | 2016-06-14 | 2023-05-24 | 리제너론 파아마슈티컬스, 인크. | 항-c5 항체 및 이의 용도 |
CN109312326B (zh) | 2016-06-17 | 2022-09-09 | 中外制药株式会社 | 抗-c5抗体及使用方法 |
TW202300168A (zh) | 2016-08-05 | 2023-01-01 | 日商中外製藥股份有限公司 | Il-8相關疾病之治療用或預防用組成物 |
SG10201908697XA (en) | 2017-01-31 | 2019-10-30 | Chugai Pharmaceutical Co Ltd | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
CN110603054B (zh) | 2017-03-06 | 2024-05-10 | 宾夕法尼亚大学理事会 | 抗c5抗体及其用途 |
CN110709101B (zh) * | 2017-03-23 | 2024-05-07 | 宾夕法尼亚大学理事会 | 抗C5a抗体及其应用 |
JP7161534B2 (ja) | 2017-11-29 | 2022-10-26 | エフ.ホフマン-ラ ロシュ アーゲー | 標的による干渉が抑制された抗薬物抗体アッセイ |
AU2018383751A1 (en) | 2017-12-13 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibody combinations and uses thereof |
CN112512563A (zh) | 2018-08-01 | 2021-03-16 | 中外制药株式会社 | 用于治疗或预防c5相关疾病的药物组合物和治疗或预防c5相关疾病的方法 |
TW202120125A (zh) | 2019-07-31 | 2021-06-01 | 瑞士商赫孚孟拉羅股份公司 | 藉由使用抗c5抗體克羅伐單抗(crovalimab)之治療或預防c5相關疾病之劑量及投藥療程 |
CN114466660A (zh) | 2019-07-31 | 2022-05-10 | 豪夫迈·罗氏有限公司 | 通过使用抗c5抗体可伐利单抗来治疗或预防c5相关疾病的剂量和施用方案 |
TW202208427A (zh) | 2020-05-06 | 2022-03-01 | 德商因夫萊亞斯有限公司 | 人源化抗c5a抗體 |
IL298923A (en) | 2020-06-16 | 2023-02-01 | Hoffmann La Roche | A method for determining the free antigen of an antibody in a sample |
WO2023050233A1 (en) * | 2021-09-29 | 2023-04-06 | The Trustees Of The University Of Pennsylvania | Humanized anti-c5a antibodies and uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4686100A (en) | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
DE3785967T2 (de) * | 1986-04-28 | 1993-12-02 | Cetus Corp | Monoklonale Antikörper gegen C5A und DES-ARG74-C5A, ihre Herstellung und ihre Verwendung. |
US5260203A (en) * | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US5256766A (en) * | 1991-02-19 | 1993-10-26 | The Regents Of The University Of California | Recombinant thrombin receptor and related pharmaceuticals |
EP0751787B1 (de) * | 1994-03-23 | 2005-01-12 | Alexion Pharmaceuticals, Inc. | Verfahren zur reduktion von fehlfunktionen des immunsystems und der hämostase während des extrakorporalen kreislaufs |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US5562904A (en) | 1994-07-21 | 1996-10-08 | Alexion Pharmaceuticals, Inc. | Retroviral transduction of cells using soluble complement inhibitors |
DE69534701T2 (de) * | 1994-09-23 | 2006-10-19 | Alexion Pharmaceuticals, Inc., Cheshire | Verfahren zur behandlung von entzündlichen gelenkerkrankungen |
US5572904A (en) * | 1995-01-05 | 1996-11-12 | Minculescu; Mihai C. | Oscillation lever arm engine |
US6673346B1 (en) | 1999-08-31 | 2004-01-06 | The Regents Of The University Of Michigan | Compositions and methods for the treatment of sepsis |
US7432356B2 (en) | 2001-08-17 | 2008-10-07 | Genentech, Inc. | Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b |
-
2002
- 2002-08-17 US US10/222,464 patent/US7432356B2/en not_active Expired - Fee Related
- 2002-08-17 MX MX2015001193A patent/MX342385B/es unknown
- 2002-08-17 BR BR0211953-6 patent/BRPI0211953B8/pt not_active IP Right Cessation
- 2002-08-17 DE DE60219801.1T patent/DE60219801T3/de not_active Expired - Lifetime
- 2002-08-17 CN CNB028161025A patent/CN100391537C/zh not_active Expired - Fee Related
- 2002-08-17 AU AU2002331601A patent/AU2002331601B2/en not_active Ceased
- 2002-08-17 CA CA2457461A patent/CA2457461C/en not_active Expired - Fee Related
- 2002-08-17 WO PCT/US2002/026074 patent/WO2003015819A1/en active IP Right Grant
- 2002-08-17 PT PT02768574T patent/PT1425042E/pt unknown
- 2002-08-17 JP JP2003520777A patent/JP4958387B2/ja not_active Expired - Lifetime
- 2002-08-17 ES ES02768574.2T patent/ES2283594T5/es not_active Expired - Lifetime
- 2002-08-17 EP EP02768574.2A patent/EP1425042B2/de not_active Expired - Lifetime
- 2002-08-17 MX MXPA04001301A patent/MXPA04001301A/es active IP Right Grant
- 2002-08-17 CN CN200810091622.4A patent/CN101387646B/zh not_active Expired - Fee Related
- 2002-08-17 AT AT02768574T patent/ATE360441T1/de active
-
2005
- 2005-05-19 HK HK05104181.6A patent/HK1071304A1/xx not_active IP Right Cessation
-
2008
- 2008-01-24 US US12/011,058 patent/US8206716B2/en not_active Expired - Fee Related
-
2010
- 2010-09-01 JP JP2010195807A patent/JP5752374B2/ja not_active Expired - Fee Related
-
2012
- 2012-05-29 US US13/482,328 patent/US8372404B2/en not_active Expired - Fee Related
-
2013
- 2013-02-05 US US13/759,687 patent/US8907072B2/en not_active Expired - Fee Related
-
2014
- 2014-11-24 US US14/551,705 patent/US20150086572A1/en not_active Abandoned
-
2016
- 2016-03-22 US US15/076,960 patent/US20160200805A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1071304A1 (en) | Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b | |
MA32928B1 (fr) | Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer | |
SG10201407388XA (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
MXPA05011886A (es) | Metodos y composiciones para la prevencion y tratamiento de septicemia. | |
NO20092718L (no) | Antagonist-anti-Notch 3-antistoffer og deres anvendelse i forebyggelsen og behandlingen av Notch 3-relaterte sykdommer | |
MA31899B1 (fr) | Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant | |
AU2006226733A8 (en) | Antibodies against CD38 for treatment of multiple myeloma | |
TW200738748A (en) | Human monoclonal antibody human CD134 (OX40) and methods of making and using same | |
MX2009004532A (es) | Composiciones y metodos para unir esfingosina-1-fosfato. | |
UA90457C2 (ru) | Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms | |
WO2002089738A3 (en) | Proteomimetic compounds and methods | |
MY155603A (en) | Notch-binding agents and antagonists and methods of use thereof | |
MX2021000398A (es) | Moleculas de anticuerpo que se unen a pd-l1 y cd137. | |
TW200505481A (en) | Compositions and methods for treating coagulation related disorders | |
MA30876B1 (fr) | Anticorps de la lymphotoxine-alpha | |
GEP20135826B (en) | Novel antibodies used to treat cancer | |
PH12020551661A1 (en) | Anti-pd-l1 antibody and use thereof | |
MX2010004615A (es) | Anticuerpos monoclonales contra proteina c. activada e inactivada. | |
MX2021012769A (es) | Anticuerpos bloqueadores cd73. | |
EP1878441A3 (de) | Komplement-Inhibitoren, die an C5 und C5a binden, ohne die Bildung von C5b zu hemmen | |
SG148190A1 (en) | Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer | |
WO2002094194A3 (en) | Compositions and methods for inhibiting metastasis | |
MX2022001411A (es) | Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5. | |
DE602005025459D1 (de) | Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum | |
MX2021008453A (es) | Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20200817 |